Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg Bartsch

Showing results (241-250 of 298) with videos related to

Pageof 30
Sort By:
BJU International|February 12, 2008
Pathological features of Gleason score 6 prostate cancers in the low and intermediate range of prostate-specific antigen level: is there a difference?Alexandre E Pelzer, Daniela Colleselli, Jasmin Bektic, et al.
BJU International|March 18, 2008
Clinical and pathological features of screen vs non-screen-detected prostate cancers: is there a difference?Alexandre E Pelzer, Daniela Colleselli, Jasmin Bektic, et al.
Oncology Reports|December 29, 2015
Autophagy-associated proteins BAG3 and p62 in testicular cancerGeorg Bartsch, Lukas Jennewein, Patrick N Harter, et al.
The American Journal of Pathology|January 1, 2003
The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor functionBarbara Comuzzi, Leonidas Lambrinidis, Hermann Rogatsch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2005
Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinomaKarin Jöhrer, Claudia Zelle-Rieser, Alexander Perathoner, et al.
The Prostate|August 21, 2007
A prospective randomized trial comparing contrast-enhanced targeted versus systematic ultrasound guided biopsies: impact on prostate cancer detectionMichael Mitterberger, Wolfgang Horninger, Alexandre Pelzer, et al.
European Urology|August 30, 2005
Are transition zone biopsies still necessary to improve prostate cancer detection? Results from the tyrol screening projectAlexandre E Pelzer, Jasmin Bektic, Andreas P Berger, et al.
BJU International|January 15, 2008
Over-diagnosis and under-diagnosis of screen- vs non-screen-detected prostate cancers with in men with prostate-specific antigen levels of 2.0-10.0 ng/mLAlexandre E Pelzer, Daniela Colleselli, Jasmin Bektic, et al.
The Journal of Steroid Biochemistry and Molecular Biology|October 24, 2006
Microbubble-enhanced ultrasound to deliver an antisense oligodeoxynucleotide targeting the human androgen receptor into prostate tumoursPetra Haag, Ferdinand Frauscher, Johann Gradl, et al.
The Journal of Urology|November 25, 2003
Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/mlWilliam J Catalona, Georg Bartsch, Harry G Rittenhouse, et al.
Pageof 30

Showing results (241-250 of 298) with videos related to

Sort By:
Pageof 30
BJU International|February 12, 2008
Pathological features of Gleason score 6 prostate cancers in the low and intermediate range of prostate-specific antigen level: is there a difference?Alexandre E Pelzer, Daniela Colleselli, Jasmin Bektic, et al.
BJU International|March 18, 2008
Clinical and pathological features of screen vs non-screen-detected prostate cancers: is there a difference?Alexandre E Pelzer, Daniela Colleselli, Jasmin Bektic, et al.
Oncology Reports|December 29, 2015
Autophagy-associated proteins BAG3 and p62 in testicular cancerGeorg Bartsch, Lukas Jennewein, Patrick N Harter, et al.
The American Journal of Pathology|January 1, 2003
The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor functionBarbara Comuzzi, Leonidas Lambrinidis, Hermann Rogatsch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2005
Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinomaKarin Jöhrer, Claudia Zelle-Rieser, Alexander Perathoner, et al.
The Prostate|August 21, 2007
A prospective randomized trial comparing contrast-enhanced targeted versus systematic ultrasound guided biopsies: impact on prostate cancer detectionMichael Mitterberger, Wolfgang Horninger, Alexandre Pelzer, et al.
European Urology|August 30, 2005
Are transition zone biopsies still necessary to improve prostate cancer detection? Results from the tyrol screening projectAlexandre E Pelzer, Jasmin Bektic, Andreas P Berger, et al.
BJU International|January 15, 2008
Over-diagnosis and under-diagnosis of screen- vs non-screen-detected prostate cancers with in men with prostate-specific antigen levels of 2.0-10.0 ng/mLAlexandre E Pelzer, Daniela Colleselli, Jasmin Bektic, et al.
The Journal of Steroid Biochemistry and Molecular Biology|October 24, 2006
Microbubble-enhanced ultrasound to deliver an antisense oligodeoxynucleotide targeting the human androgen receptor into prostate tumoursPetra Haag, Ferdinand Frauscher, Johann Gradl, et al.
The Journal of Urology|November 25, 2003
Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/mlWilliam J Catalona, Georg Bartsch, Harry G Rittenhouse, et al.
Pageof 30